5 research outputs found
Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model
The limited efficacy of current treatments against pancreatic cancer has prompted the search of new
alternatives such as virotherapy. Activation of the immune response against cancer cells is emerging as one of the
main mechanisms of action of oncolytic viruses (OV). Direct oncolysis releases tumor antigens, and viral replication
within the tumor microenvironment is a potent danger signal. Arming OV with immunostimulatory transgenes
further enhances their therapeutic effect. However, standard virotherapy protocols do not take full advantage of OV
as cancer vaccines because repeated viral administrations may polarize immune responses against strong viral
antigens, and the rapid onset of neutralizing antibodies limits the efficacy of redosing. An alternative paradigm
based on sequential combination of antigenically distinct OV has been recently proposed
Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model
The limited efficacy of current treatments against pancreatic cancer has prompted the search of new
alternatives such as virotherapy. Activation of the immune response against cancer cells is emerging as one of the
main mechanisms of action of oncolytic viruses (OV). Direct oncolysis releases tumor antigens, and viral replication
within the tumor microenvironment is a potent danger signal. Arming OV with immunostimulatory transgenes
further enhances their therapeutic effect. However, standard virotherapy protocols do not take full advantage of OV
as cancer vaccines because repeated viral administrations may polarize immune responses against strong viral
antigens, and the rapid onset of neutralizing antibodies limits the efficacy of redosing. An alternative paradigm
based on sequential combination of antigenically distinct OV has been recently proposed
Characterization of Critical Determinants of ACE2–SARS CoV-2 RBD Interaction
Despite sequence similarity to SARS-CoV-1, SARS-CoV-2 has demonstrated greater widespread virulence and unique challenges to researchers aiming to study its pathogenicity in humans. The interaction of the viral receptor binding domain (RBD) with its main host cell receptor, angiotensin-converting enzyme 2 (ACE2), has emerged as a critical focal point for the development of anti-viral therapeutics and vaccines. In this study, we selectively identify and characterize the impact of mutating certain amino acid residues in the RBD of SARS-CoV-2 and in ACE2, by utilizing our recently developed NanoBiT technology-based biosensor as well as pseudotyped-virus infectivity assays. Specifically, we examine the mutational effects on RBD-ACE2 binding ability, efficacy of competitive inhibitors, as well as neutralizing antibody activity. We also look at the implications the mutations may have on virus transmissibility, host susceptibility, and the virus transmission path to humans. These critical determinants of virus–host interactions may provide more effective targets for ongoing vaccines, drug development, and potentially pave the way for determining the genetic variation underlying disease severity
Recommended from our members
Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy
Recent advances in cancer therapeutics clearly demonstrate the need for innovative multiplex therapies that attack the tumour on multiple fronts. Oncolytic or "cancer-killing" viruses (OVs) represent up-and-coming multi-mechanistic immunotherapeutic drugs for the treatment of cancer. In this study, we perform an in-vitro screen based on virus-encoded artificial microRNAs (amiRNAs) and find that a unique amiRNA, herein termed amiR-4, confers a replicative advantage to the VSVΔ51 OV platform. Target validation of amiR-4 reveals ARID1A, a protein involved in chromatin remodelling, as an important player in resistance to OV replication. Virus-directed targeting of ARID1A coupled with small-molecule inhibition of the methyltransferase EZH2 leads to the synthetic lethal killing of both infected and uninfected tumour cells. The bystander killing of uninfected cells is mediated by intercellular transfer of extracellular vesicles carrying amiR-4 cargo. Altogether, our findings establish that OVs can serve as replicating vehicles for amiRNA therapeutics with the potential for combination with small molecule and immune checkpoint inhibitor therapy